2022年ESC/EACTS联合审查:2018年指南中左主干冠状动脉疾病低手术风险且解剖适合PCI或CABG患者的血运重建推荐
2022年ESC/EACTS联合工作组审查2018年指南中左主干病变低至中危SYNTAX评分(0-32)患者的血运重建推荐。工作组汇总四项随机试验的更新数据,建议CABG为I类推荐A级证据,PCI为IIa类推荐A级证据;对于解剖适合两种术式且预测手术死亡率低的稳定患者,两种方案均合理。
要点
- CABG推荐为I类推荐,A级证据;PCI推荐为IIa类推荐,A级证据。
- 稳定患者解剖适合两种术式且预测手术死亡率低时,两种方案均合理。
- 四项随机试验汇总数据仅足以排除死亡率的较大差异。
核心结论
- 对于因左主干病变需血运重建的稳定患者,若解剖适合两种术式且预测手术死亡率低,工作组认为基于患者偏好、现有技术和当地术者手术量,两种治疗选择在临床上均合理。
- 建议的CABG血运重建推荐为I类推荐,A级证据;PCI推荐为IIa类推荐,A级证据。
研究设计与样本
- 2021年10月,欧洲心脏病学会(ESC)与欧洲心胸外科协会(EACTS)联合成立工作组,审查2018年ESC/EACTS心肌血运重建指南中关于左主干病变(低至中危SYNTAX评分0-32)患者的推荐。
- 工作组审查了自2018年指南以来所有新的相关数据,包括比较PCI(药物洗脱支架)与CABG在左主干病变患者中的四项随机试验的更新汇总数据。
主要发现
- 工作组指出,四项随机试验的汇总数据仍仅足以排除死亡率的较大差异。
- 工作组识别出与左主干病变血运重建相关的若干重要知识空白。
关键数值与推荐
- 建议的CABG血运重建推荐为I类推荐,A级证据。
- 建议的PCI推荐为IIa类推荐,A级证据。
临床怎么用
- 对于因左主干病变需血运重建的稳定患者,若解剖适合两种术式且预测手术死亡率低,工作组认为基于患者偏好、现有技术和当地术者手术量,两种治疗选择在临床上均合理。
- 建议的CABG推荐为I类推荐,A级证据;PCI推荐为IIa类推荐,A级证据。
局限性
- 工作组识别出与左主干病变血运重建相关的若干重要知识空白。
- 四项随机试验的汇总数据仍仅足以排除死亡率的较大差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Task Force structure and summary of clinical evidence of 2022 ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease. CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; LM, left main; SYNTAX, Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery. a'Event' refers to the composite of death, myocardial infarction (according to Universal Definition of Myocardial Infarction if available, otherwise protocol defined) or stroke. In October 2021, the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) jointly agreed to establish a Task Force (TF) to review recommendations of the 2018 ESC/EACTS Guidelines on myocardial revascularization as they apply to patients with left main (LM) disease with low-to-intermediate SYNTAX score (0-32). This followed the withdrawal of support by the EACTS in 2019 for the recommendations about the management of LM disease of the previous guideline. The TF was asked to review all new relevant data since the 2018 guidelines including updated aggregated data from the four randomized trials comparing percutaneous coronary intervention (PCI) with drug-eluting stents vs. coronary artery bypass grafting (CABG) in patients with LM disease. This document represents a summary of the work of the TF; suggested updated recommendations for the choice of revascularization modality in patients undergoing myocardial revascularization for LM disease are included. In stable patients with an indication for revascularization for LM disease, with coronary anatomy suitable for both procedures and a low predicted surgical mortality, the TF concludes that both treatment options are clinically reasonable based on patient preference, available expertise, and local operator volumes. The suggested recommendations for revascularization with CABG are Class I, Level of Evidence A. The recommendations for PCI are Class IIa, Level of Evidence A. The TF recognized several important gaps in knowledge related to revascularization in patients with LM disease and recognizes that aggregated data from the four randomized trials were still only large enough to exclude large differences in mortality.
引用
- Byrne RA, Fremes S, Capodanno D, et al. 2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG. Eur J Cardiothorac Surg. 2023. PMID: 37632766. doi:10.1093/ejcts/ezad286
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。